Patrizia Larghero
Overview
Explore the profile of Patrizia Larghero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
275
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benz T, Larghero P, Meyer C, Muller M, Bruggmann D, Hentrich A, et al.
STAR Protoc
. 2024 Dec;
6(1):103481.
PMID: 39700011
KMT2A rearrangements are associated with a poor clinical outcome in infant, pediatric, and adult acute lymphoblastic and myeloid leukemia. Here, we present a protocol to reconstruct chromosomal translocations with different...
2.
Maurer-Granofszky M, Kohrer S, Fischer S, Schumich A, Nebral K, Larghero P, et al.
Haematologica
. 2024 Jul;
109(7):2379-2381.
PMID: 38946650
No abstract available.
3.
Burmeister T, Stroh A, Kehden B, Trautmann H, Meyer C, Marschalek R, et al.
Leukemia
. 2024 Mar;
38(7):1600-1603.
PMID: 38519799
No abstract available.
4.
Lopes B, Meyer C, Bouzada H, Kulp M, Maciel A, Larghero P, et al.
Leukemia
. 2023 Jun;
37(8):1727-1731.
PMID: 37386080
No abstract available.
5.
Maurer-Granofszky M, Kohrer S, Fischer S, Schumich A, Nebral K, Larghero P, et al.
Haematologica
. 2023 Jun;
109(3):740-750.
PMID: 37345487
Pediatric acute myeloid leukemia (AML) is a highly heterogeneous disease making standardized measurable residual disease (MRD) assessment challenging. Currently, patient-specific DNA-based assays are only rarely applied for MRD assessment in...
6.
Kulp M, Larghero P, Alten J, Cario G, Eckert C, Caye-Eude A, et al.
Leukemia
. 2023 Apr;
37(6):1216-1233.
PMID: 37100882
KMT2A-rearranged acute lymphoblastic infant leukemia (KMT2A-r iALL) is associated with outsize risk of relapse and relapse mortality. We previously reported strong upregulation of the immediate early gene EGR3 in KMT2A::AFF1...
7.
Kulp M, Siemund A, Larghero P, Dietz A, Alten J, Cario G, et al.
iScience
. 2022 Jul;
25(7):104613.
PMID: 35800767
The most frequent genetic aberration leading to infant ALL (iALL) is the chromosomal translocation t(4;11), generating the fusion oncogenes : and :, respectively. -r iALL displays a dismal prognosis through...
8.
Kowarz E, Krutzke L, Kulp M, Streb P, Larghero P, Reis J, et al.
Elife
. 2022 Jan;
11.
PMID: 35084333
To fight the COVID-19 pandemic caused by the RNA virus SARS-CoV-2, a global vaccination campaign is in progress to achieve the immunization of billions of people mainly with adenoviral vector-...
9.
de Matos R, Ferreira G, Meyer C, Marschalek R, Larghero P, Ribeiro R, et al.
J Pediatr Hematol Oncol
. 2021 Dec;
44(3):e719-e722.
PMID: 34966090
About 25% of the patients with the translocation t(11;19)(q23;p13.3)/KMT2A-MLLT1 present three-way or more complex fusions, associated with a worse prognosis, suggesting that a particular mechanism creates functional KMT2A fusions for...
10.
Bataller A, Guijarro F, Caye-Eude A, Strullu M, Sterin A, Molina O, et al.
Blood Adv
. 2021 Oct;
5(24):5617-5620.
PMID: 34638131
No abstract available.